X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Wockhardt with ACTAVIS INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WOCKHARDT vs ACTAVIS (US) - Comparison Results

WOCKHARDT    Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 WOCKHARDT   ACTAVIS
EQUITY SHARE DATA
    WOCKHARDT
Mar-18
ACTAVIS
Dec-18
WOCKHARDT/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs1,01213,413-   
Low Rs5328,998-   
Sales per share (Unadj.) Rs355.93,290.3-  
Earnings per share (Unadj.) Rs-60.3-1,059.8-  
Cash flow per share (Unadj.) Rs-46.8346.7-  
Dividends per share (Unadj.) Rs0.010-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs257.813,571.0-  
Shares outstanding (eoy) m110.63332.60-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.23.4 63.7%   
Avg P/E ratio x-12.8-10.6 121.1%  
P/CF ratio (eoy) x-16.532.3 -51.1%  
Price / Book Value ratio x3.00.8 362.5%  
Dividend payout %00-   
Avg Mkt Cap Rs m85,3793,726,975 2.3%   
No. of employees `0006.316.9 37.0%   
Total wages/salary Rs m9,3710-   
Avg. sales/employee Rs Th6,295.064,754.7 9.7%   
Avg. wages/employee Rs Th1,498.30-   
Avg. net profit/employee Rs Th-1,066.3-20,857.5 5.1%   
INCOME DATA
Net Sales Rs m39,3691,094,355 3.6%  
Other income Rs m1,20220,928 5.7%   
Total revenues Rs m40,5711,115,283 3.6%   
Gross profit Rs m1828,678 0.1%  
Depreciation Rs m1,495467,813 0.3%   
Interest Rs m2,55563,151 4.0%   
Profit before tax Rs m-2,830-481,358 0.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-3,582122,766 -2.9%   
Tax Rs m257-6,100 -4.2%   
Profit after tax Rs m-6,669-352,492 1.9%  
Gross profit margin %02.6 1.8%  
Effective tax rate %-9.11.3 -716.7%   
Net profit margin %-16.9-32.2 52.6%  
BALANCE SHEET DATA
Current assets Rs m33,796448,847 7.5%   
Current liabilities Rs m26,917397,065 6.8%   
Net working cap to sales %17.54.7 369.3%  
Current ratio x1.31.1 111.1%  
Inventory Days Days7920 405.1%  
Debtors Days Days8966 134.6%  
Net fixed assets Rs m39,664123,875 32.0%   
Share capital Rs m5530-   
"Free" reserves Rs m27,9680-   
Net worth Rs m28,5224,513,702 0.6%   
Long term debt Rs m21,7311,589,438 1.4%   
Total assets Rs m81,6207,055,944 1.2%  
Interest coverage x-0.1-6.6 1.6%   
Debt to equity ratio x0.80.4 216.4%  
Sales to assets ratio x0.50.2 311.0%   
Return on assets %-5.0-4.1 122.9%  
Return on equity %-23.4-7.8 299.4%  
Return on capital %-7.7-4.8 158.5%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m8,0190-   
CASH FLOW
From Operations Rs m684390,972 0.2%  
From Investments Rs m6,302214,788 2.9%  
From Financial Activity Rs m-7,695-671,025 1.1%  
Net Cashflow Rs m-664-64,939 1.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 69.32 Rs / USD

Compare WOCKHARDT With: ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  

Compare WOCKHARDT With: STERLING BIOTECH  NOVARTIS  SANOFI INDIA  STRIDES PHARMA SCIENCE  UNICHEM LAB  



Today's Market

Indian Indices End Higher, IPO Buzz, and Top Cues in Focus Today(Pre-Open)

On Tuesday, Indian share markets witnessed most of the buying interest during closing hours and ended their trading session on a strong note.

Related Views On News

WOCKHARDT Announces Quarterly Results (4QFY19); Net Profit Up 90.8% (Quarterly Result Update)

May 7, 2019 | Updated on May 7, 2019

For the quarter ended March 2019, WOCKHARDT has posted a net profit of Rs 139 m (up 90.8% YoY). Sales on the other hand came in at Rs 10 bn (down 3.8% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

WOCKHARDT LTD. Announces Quarterly Results (3QFY19); Net Profit Down 80.6% (Quarterly Result Update)

Jan 29, 2019 | Updated on Jan 29, 2019

For the quarter ended December 2018, WOCKHARDT LTD. has posted a net profit of Rs 769 m (down 80.6% YoY). Sales on the other hand came in at Rs 10 bn (up 4.0% YoY). Read on for a complete analysis of WOCKHARDT LTD.'s quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

7 Stocks That Will Remain Evergreen in this Era of Technological Disruption(The 5 Minute Wrapup)

Jun 13, 2019

We are living in an era of disruption. Are your stocks well equipped to adapt to changes that disruption will bring along?

Why I Believe Smallcaps Will Catch up to the Sensex(Profit Hunter)

Jun 14, 2019

Smallcaps have gone nowhere even as the Sensex makes new all-time highs. Find out why Richa believes this a good opportunity to invest in smallcaps.

Why Super Investor Kenneth Andrade is Bullish on Agri Stocks...and So Are We(The 5 Minute Wrapup)

Jun 21, 2019

Andrade gives his take on agriculture, an industry from which we have already recommended two stocks.

This Little-Known Opportunity Promises Both Health and Wealth for Your Grandchildren(Profit Hunter)

Jun 20, 2019

The next big opportunity that has the potential to make you both rich and healthy.

My Upcoming Stock Recommendation, Backed by Aberdeen Standard Investments, Scores 9.1/10(The 5 Minute Wrapup)

Jun 19, 2019

This month's Smart Money Secrets recommendation is from global super investor - Aberdeen Standard Investments.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

WOCKHARDT SHARE PRICE


Jun 25, 2019 (Close)

TRACK WOCKHARDT

  • Track your investment in WOCKHARDT with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

WOCKHARDT - JUBILANT LIFE SCIENCES COMPARISON

COMPARE WOCKHARDT WITH

MARKET STATS